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Sj¨ ogren’s syndrome (SjS) is a complex chronic autoimmune disease of unknown etiology which primarily targets the exocrine
glands, resulting in eventual loss of secretory function. The disease can present as either primary SjS or secondary SjS, the latter
of which occurs concomitantly with another autoimmune disease such as rheumatoid arthritis, systemic lupus erythematosus,
scleroderma, or primary biliary cirrhosis. Current advancements in therapeutic prevention and treatment for SjS are impeded
by lack of understanding in the pathophysiological and clinical progression of the disease. Development of appropriate mouse
models for both primary and secondary SjS is needed in order to advance knowledge of this disease. This paper details important
features,advantages,andpitfallsofcurrentanimalmodelsofSjS,includingspontaneous,transgenic,knockout,immunization,and
transplantation chimera mouse models, and emphasizes the need for a better model in representing the human SjS phenotype.
1.Introduction
Sj¨ ogren’s syndrome (SjS) is a systemic chronic autoimmune
disease that targets the exocrine glands, predominantly the
salivary glands and lacrimal glands, resulting in xerostomia
(dry mouth) and keratoconjunctivitis sicca (dry eyes) [1].
The disease also presents with systemic manifestations
involving the destruction of the thyroid gland [2], lungs
[3], liver [4], and kidneys [5]. The National Arthritis Data
Workgroup using the Olmsted County, MN and 2005 US
population prevalence estimates from the Census Bureau
has estimated that the prevalence of primary SjS (pSjS) in
the USA approaches 1.3 million with a range of 0.4–3.1
million of the approximate 214.8 million population, with
a female-to-male ratio of about 9:1, indicating a probable
correlation between disease development and sex hormones
[6]. SjS can exist in one of two forms, either primary or
secondary [7]. pSjS aﬀects salivary and/or lacrimal glands
in the absence of other rheumatic diseases, while its more
common secondary form occurs in the presence of other
rheumatic diseases, such as systemic lupus erythematosus
(SLE) [8], rheumatoid arthritis (RA) [9], scleroderma [10],
and primary biliary cirrhosis [11] .T h ed e g r e eo fg l a n d u l a r
destruction is related to the progressive development of
lymphocytic inﬁltrations which are composed primarily of
CD4+ and CD8+ T cells [12], B cells [13], macrophages, and
dendritic cells [14].
According to the revised European-American Consensus
Group criteria, diagnosis of SjS includes signs of ocular and
oral dryness, detection of inﬁltrating lymphocytes within
minor salivary glands with quantiﬁcation determined by
histopathological evaluation, and the presence in serum of
autoantibodies, speciﬁcally anti-SSA/Ro, anti-SSB/La, and
antinuclear antibodies (ANA) [15]. Recently, considerable
interest has focused attention on serological evaluations
showing the presence of rheumatoid factor (RF), elevated
immunoglobulin levels (hypergammaglobulinemia), anti-α-
fodrin, and the presence of antibodies to the muscarinic
acetylcholine receptors, especially the type 3 receptor (M3R)
which could impair secretory function [16–24].2 Journal of Biomedicine and Biotechnology
The precise etiology of SjS remains elusive; however, a
number of possible theories have been postulated. Envi-
ronmental triggers including exposure to Epstein-Barr virus
[25], hepatitis C virus [26], and retroviruses including both
h u m a nT - c e l ll y m p h o c y t i cv i r u st y p eI( H T L V - 1 )[ 27]a n d
human endogenous retrovirus (HERV-K113) [28], may ini-
tiate epithelial cell activation and a prolonged inﬂammatory
response in genetically predisposed individuals, resulting
in systemic autoimmunity. Other hypotheses, including
epithelial/acinar cell apoptosis, emergence of autoreactive
T cells, eﬀect of autoantibodies and neurological dys-
function, could consequently contribute to various aspects
of SjS pathogenesis [29]. The challenge of attempting to
understand the mechanism of human SjS pathogenesis is
the inability to learn the biological and immunological
occurrence prior to overt clinical signs. End-stage disease is
often the only parameter which is used to characterize the
entire disease process. As a result, it remains diﬃcult to grasp
and understand the disease development. Therefore, animal
models for SjS would permit the investigation of the full
spectrumofpossibleetiologiesfrompriortoduringandafter
disease development.
An ideal SjS mouse model should fulﬁll a range of com-
mon characteristics present in human SjS, including etiolog-
ical, clinical, histological, serological, and immunobiological
features as detailed in Table 1. Furthermore, diﬀerent models
will represent SjS in either its primary or secondary form,
as demonstrated in Table 2 which clariﬁes the relevance of
each mouse model. This paper will provide a comprehensive
examination of many animal models of SjS that mimic fully
or various pathological aspects of human SjS.
2. Spontaneous Mouse Models for
Sj¨ ogren’s Syndrome
2.1. Nonobese Diabetic Mice. The nonobese diabetic (NOD)
inbred strain of mice were developed from a cataract-prone
subline (CTS) derived from outbred ICR mice [33]. The
NOD strain is not cataract-prone, however, and is most
commonly used as a model for human Type 1 insulin-
dependent diabetes mellitus (IDDM or T1D) due to lym-
phocytic inﬁltrations (insulitis) which cause the destruction
of pancreatic islets. Onset of diabetes in highly inbred NOD
mice occurs between 90 and 120 days, with an incidence of
60–80% in females and 20–30% in males by 210 days [34].
Spontaneous onset of diabetes in NOD mice presents with
hyperglycemia, hypercholesterolemia, glycosuria, ketonuria,
polyuria, polydipsia, and polyphagia, all common clinical
features of human IDDM. While insulitis develops by 4
weeks (wks) of age, lymphocytic inﬁltrations in the salivary
and lacrimal glands occur at approximately 12–16wks of
age with corresponding loss of secretory function by 20wks
old [35, 36]. At the onset of SjS-like disease, various signa-
ture autoantibodies can also be detected, speciﬁcally, anti-
SSA/Ro, anti-SSB/La and anti-muscarinic receptor type III
(M3R) which has been demonstrated to directly contribute
to the secretory dysfunction in this animal model and SjS
patients.
The NOD mouse model has provided important insight
into the genetics of human SjS. The development of T1D in
the NOD mouse is controlled by more than 18 chromosomal
regions [37]. Early studies involving replacement of individ-
ual insulin-dependent diabetes (idd) susceptibility intervals
such as Idd3, Idd5, Idd13, Idd1,a n dIdd9 had minimal eﬀect
on the development of autoimmune exocrinopathy or SjS-
likedisease.BothIdd3andIdd5arerequiredfordevelopment
of salivary and lacrimal dysfunction [38]. When both
NOD-derived genetic regions were introduced to the SjS
nonsusceptible C57BL/6 strain by crossing C57BL/6.NODc3
mice carrying Idd3 (Autoimmune exocrinopathy 1 (Aec1))
locusand C57BL/6.NODc1t micecarrying Idd5 (Aec2)locus,
the C57BL/6.NODc3.NODc1t or C57BL/6.NOD-Aec1Aec2
m o u s es t r a i nw a sp r o d u c e dw h i c hi sh o m o z y g o u sf o rb o t h
Idd3 and Idd5 chromosomal intervals [39]. This double
congenic strain fully recapitulated the SjS-like disease pro-
cess, exhibiting pathophysiological changes at early age,
followed by lymphocytic inﬁltrations of the salivary and
lacrimal glands at 12–16wks of age, then accompanied
by the production of autoantibodies to nuclear antigens
(SSA/Ro, SSB/La) and M3R in the absence of T1D. The
lymphocytic foci (LF) consisted mainly of CD4+ and CD8+
T cells, as well as B lymphocytes with associated loss of
saliva production by 20wks of age. Due to the presence
of T cells and sporadic numbers of dendritic cells and
macrophages within inﬁltrates, an increase in the levels of
proinﬂammatory cytokines such as interleukin-17 (IL-17),
IL-22, and IL-23 was also detected locally and systemically.
Similar observations are observed in human SjS patients
[40].
A recombinant inbred line, known as C57BL/6.NOD-
Aec1R1Aec2, was developed to deﬁne smaller genetic regions
that contain those genes necessary to induce autoimmune
exocrinopathy by narrowing the Aec1 region [41]. The
genetic region of Aec1 locus was shortened from a 48.5cm
segment to a centromeric piece spanning 19.2cm. The
resultant strain exhibited more rapid SjS-like disease in
males, with males developing salivary gland inﬁltrations
at 10wks of age compared to 19wks in females. Females
presented with more severe sialadenitis and larger inﬁl-
trations in the submandibular gland by 22wks; however,
they exhibited no dacryoadenitis whereas males exhibited
signiﬁcantly high levels of dacryoadenitis. Furthermore, a
homogeneous nuclear ANA pattern was apparent in males
as early as 5wks of age but not until 10wks in females. Both
sexes demonstrated a signiﬁcant loss of saliva ﬂow rate (35–
40%) beginning at 5wks of age, but only males displayed a
lossoflacrimalglandsecretoryfunction. Thelackof lacrimal
gland dysfunction in females may be attributed to the loss of
a necessary gene on the shortened Aec1 locus which could
regulate the sex dimorphism presented in SjS.
Interestingly, the major histocompatibility complex
(MHC) genes have little or no relation to the development
of SjS in the NOD mouse. For example, the MHC class II
region, when replaced from Ag7 to Ab locus in NOD mice,
prevented the development of T1D, but the onset of SS-like
disease remained unaﬀected[42]. Also, the NOD.H2h4 strain
presents with exocrine gland inﬁltrations and compromisedJournal of Biomedicine and Biotechnology 3
Table 1: Important criterion for an ideal primary SjS mouse model.
Features
Etiology Unknown (possible viral exposure)
Clinical Xerostomia
Keratoconjunctivitis sicca
Histological
Polyclonal lymphocytic inﬁltrations in the salivary and lacrimal glands
Lymphocytic focus, > 50 mononuclear cells/mm2 (CD4+ > CD8+)
Monoclonal B cell proliferation
Progressive destruction of the acinar and ductal cells
Serological
Hypergammaglobulinemia
Anti-SSA/Ro and anti-SSB/La autoantibodies
Anti-α-fodrin autoantibody
Rheumatoid factor
Antinuclear antibodies
Anti-type 3 acetylcholine muscarinic receptor
Additional organ involvement Heart, blood vessels, lungs, liver, pancreas, stomach, kidneys, bladder, thyroid gland (secondary SjS)
Immunobiology
Diminished apoptosis of lymphocytes
Abnormal MHC expression, H2+-glandular ductal epithelium
Epithelial cell expression of Fas/FasL
Other 9:1female:maleratio
Disease presents in absence of other rheumatic diseases
Table 2: Primary and secondary SjS mouse models.
Type of SjS Mouse Model Secondary to
Primary
Aec1Aec2 —
NOD.B10-H2b —
NFS/sld —
IQI/Jic —
CAII immunization —
PI3K K.O. —
ID3 K.O. —
Ar K.O. —
Ro immunization —
Aly/aly —
Secondary
NOD Autoimmune diabetes
NOD.H2h4 Autoimmune thyroiditis
MRL/lpr RA, SLE
GVHR SLE
BAFF Tg SLE
IL-12 Tg SLE
IL-14α Tg SLE
MCMV SLE
HTLV-1 tax Tg RA [30]
TGF-β1 K.O. SLE [31]
IL-6 Tg IL-10 Tg PBC [32]SLE/Neuropathy
TSP-1 K.O. IBS
K.O.: knockout; Tg: transgenic; SLE: systemic lupus erythematosus; RA:
rheumatoid arthritis; PBC: primary biliary cirrhosis; IBS: inﬂammatory
bowel disease.
salivaﬂowwithoutsymptomsofT1Dduetothereplacement
of the Ag7 allele with I-Ak, but continues to develop
spontaneous thyroiditis at a low occurrence (5%) [43, 44].
The NOD.B10-H2b strain also demonstrates an SjS-like
phenotype with inﬂammatory inﬁltrations in the exocrine
glandswithouttheoccurrenceofT1Dduetothereplacement
of the diabetogenic MHC locus with the MHC locus of
C57BL/10 strain that is nonsusceptible to T1D [45, 46]. As a
result, the NOD and NOD-derived animal models have been
critical in elucidating the genetic basis of SjS development.
2.2. NZB/W F1 Mice. The ﬁrst mouse model for sponta-
neous SjS was the NZB/W F1 hybrid described in 1968
[47]. By crossing the ﬁrst ﬁlial generation New Zealand
black (NZB) mouse with the New Zealand white (NZW)
mouse, the NZB/W F1 hybrid was produced, which spon-
taneously developed disease characteristic of SjS and SLE
[48]. Mononuclear cell inﬁltrations were present in both
salivary and lacrimal glands by 4 months of age, with more
severe lesions in the lacrimal glands of females. Epithelial
cell nodules were also present, as well as edematous changes,
necrosis, and connective tissue replacement of parenchyma.
The primary composition of inﬁltrations was T cells with
lower numbers of B cells [49]. Hypergammaglobulinemia,
pulmonary vasculitis, nuclear autoantibodies, reduced com-
plement levels, and circulating immune complexes were also
presented in this mouse model [50].
2.3. MRL/lpr Mice. The MRL/lpr mouse was developed with
a genetic mutation of the lymphoproliferation (lpr)g e n e
on chromosome 19 which encodes the structural gene for
the Fas antigen [51]. The MRL-lpr/lpr mouse spontaneously
develops disease similar to SLE [52]a n dR A[ 53], charac-
terized by splenomegaly, arthritis, glomerulonephritis, and
massive lymphadenopathy [54]. This model develops an SjS-
likephenotypebeginningat2monthsofagewiththeonsetof
inﬂammatory inﬁltrations within the submandibular glands,
followed by a less severe inﬂammation in the parotid and4 Journal of Biomedicine and Biotechnology
sublingual glands. Although an early report suggested that
MRL mice do not synthesize anti-SSA/Ro and anti-SSB/La
auto-antibodies [55], more recent reports indicate that
nearly 30% of mice develop anti-52KDa SSA/Ro antibodies,
6% develop anti-60KDa SSA/Ro antibodies, and 6% develop
anti-SSB/La antibodies, but not SSA/Ro [56]. Due to the
defect in the Fas antigen which controls apoptosis, the
MRL/lpr mice develop aggressive autoimmune lymphopro-
liferation contributed by the autoreactive lpr T cells which
have escaped thymic selection [51].
2.4. NFS/sld Mice. The NFS/sld mouse bears a mutation in
the sublingual gland diﬀerentiation arrest (sld) gene which
aﬀects acinar cell diﬀerentiation into mucous-secreting cells
in the sublingual gland [57]. At three days of age, the NFS/sld
mice are thymectomized without any prior immunization;
these mice develop a spontaneous pSjS-like disease [58].
Severe inﬂammatory inﬁltrations develop after 4 wks of
age in both salivary and lacrimal glands that are composed
mainly of CD3+ and CD4+ T cells with a lesser number of
CD8+ T cells and B220+ B cells. No inﬂammatory lesions
are present in other organs, nor in nonthymectomized mice.
Female mice develop a more severe diseased phenotype.
NFS/sld mice which developed inﬁltrations in the glands
had signiﬁcant levels of IgG autoantibodies in sera. The
organ-speciﬁc 120-kilodalton α-fodrin autoantigen which
has high sequence homology with the human cytoskeleton
protein α-fodrin was found within the salivary glands of
NFS/sld mutant mice, indicating a potential role in the
development of sialadenitis and dacryoadenitis [59]. The
early accumulation of α-fodrin within the salivary glands
mayleadtotheobservedlossofsecretoryfunctionby18wks;
however, this is most likely due to aging rather than SjS-like
disease phenotype [60].
2.5. IQI/Jic Mice. The IQI/Jic mouse is an inbred strain
established from the Imprinting Control Region (ICR)
mousestrainsimilartoNOD.Thesemiceproduceantinucle-
olar autoantibody in response to mercuric chloride exposure
[61]. The strain is marked by an increase in the number
of B cells within the thymus of aged females, as well as
the presence of mononuclear cell inﬁltrations within the
salivary and lacrimal glands. The major composition of
inﬂammatory inﬁltrations is reportedly B220+ B cells, with
a lesser numbers of CD4+ T cells. Concomitantly, acinar
cell destruction is observed around large foci. However,
small foci consist primarily of CD4+ cells, indicating that
B cells continuously invade the aﬀected organs as the
disease progresses. Sialadenitis is present in 80% of female
mice with lesions beginning at 6 months of age, and one-
third of the animals produce speckled-type IgG antinuclear
autoantibody by 15 months of age. Neither anti-SSA/Ro
nor anti-SSB/La autoantibodies were detected. Expression
of MHC class II antigen is apparent in the ductal epithelial
cells surrounding LF. Additionally, lymphocytic inﬁltrations
are also observed in the pancreas, kidneys, and lungs as the
IQI/Jic mice aged [62]. Enhanced expression of kallikrein-
13 (Klk-13) has been detected in salivary glands, suggesting
that Klk-13 may be a candidate autoantigen in SjS that
could contribute to the development of sialadenitis due to
increased T cell response to organs expressing Klk-13 [63].
2.6. Aly/aly Mice. The aly/aly mouse possesses the homozy-
gous autosomal recessive mutation alymphoplasia (aly)g e n e ,
resulting in loss of lymph nodes and Peyer’s patches [64].
Subsequently, aly/aly micereadily acceptallogenic skin grafts
and demonstrate impaired response to T cell-dependent
antigens due to absence of germinal center formation. These
mice spontaneously develop an SjS-like phenotype by 14wks
of age, with worsening disease as they aged, presenting with
chronic salivary and lacrimal gland inﬂammation as well
as inﬂammation of the exocrine glands of the pancreas.
Both lung and exocrine gland inﬁltrations are apparent, with
inﬁltrating cells being primarily CD4+CD8− T cells. Both
salivary and lacrimal glands demonstrate lymphocytic accu-
mulation within periductal areas spanning to the lobules,
and lacrimal glands show signiﬁcant degeneration of acinar
cells surrounding inﬁltrations. Tissue damage is minor or
absent in salivary glands of aged mice, and the liver shows
mild lymphoid cell inﬁltration. No autoantibodies to self-
antigens or nuclear components are apparent, likely due to
extreme defects in humoral immunity.
3.Transgenic MouseModels
3.1. HTLV-1 Tax Transgenic (Tg) Mice. Human T-cell
leukemia virus 1 (HTLV-1) is a retrovirus involved in
adult T-cell leukemia as well as in the pathogenesis of
autoimmune diseases such as SjS, RA, and possibly multiple
sclerosis (MS) [65]. Transgenic mice containing the HTLV-
1 tax gene under the control of the viral long terminal
repeat (LTR) acquires an autoimmune phenotype which
targeted the exocrine glands [27]. At early age, HTLV-1
tax transgenic mice have rapid proliferation of epithelial
cells with subsequent ductal proliferation, causing distortion
of the salivary gland architecture. Lymphocytic inﬁltrations
were observed juxtapose to epithelial cells in the salivary
and lacrimal glands. However, lacrimal glands develop less
severe inﬁltrations with onset occurring much later than in
the salivary glands. Massive LF develop between 6–8 months
of age with subsequent destruction of acinar tissues. The
degree of destruction corresponds with the level of tax gene
expression in the ductal epithelium, suggesting that HTLV-
1 may be tropic for ductal epithelial cells in the exocrine
glands. Therefore, it is postulated that HTLV-1 may trigger
the viral induction of inﬂammatory lesions via initiation of
proliferation and lymphocytic inﬁltrations. However, disease
etiology in this mouse model is likely diﬀerent from that in
human pSjS in which lymphocytic inﬁltration occurs before
proliferation of ductal cells.
3.2. Cytokine Overexpression Models
3.2.1. IL-6 Transgenic Mice. Interleukin-6 is a cytokine
that inﬂuences the immune response, participating inJournal of Biomedicine and Biotechnology 5
autoimmune disease development and pathogenesis of
liver disease. Using a murine graft-versus-host reaction
(GVHR) model with MHC class II disparity, the amount of
autoimmune-like lesions were examined to observe a diﬀer-
ence in transgenic mice with high IL-6 concentrations. The
GVHR IL-6 transgenic mice had increased IL-6 serum levels
and antimitochondrial antibodies (AMA), larger spleen
indexes, and weakened autoimmune-like lesions of the liver,
pancreas, and salivary glands when compared to controls.
There is a discrepancy between AMA titers and histological
features in IL-6 Tg mice, indicating that AMA production
may be a result of polyclonal activation of B cells upon
stimulation by IL-6. Results indicate IL-6 may inﬂuence the
pathogenesis of SjS [32].
3.2.2. IL-10 Transgenic Mice. Interleukin-10 (IL-10) is a
cytokine that may contribute to inﬂammation and patho-
genesis in various autoimmune diseases, due to its function
in regulating the proliferation and diﬀerentiation of B
cells and in enhancing MHC class II antigen expression
[66]. IL-10 has also been shown to induce expression of
cell adhesion molecules on endothelial cells and to trigger
apoptotic cell death [67]. IL-10 Tg mice were generated
by using the human salivary amylase promoter to regulate
IL-10 gene expression [68]. Elevated expression levels of
IL-10 are observed in the salivary and lacrimal glands.
Histological examination conﬁrmed the presence of inﬂam-
matory lesions within the exocrine glands in 8wks old
mice, with concomitant decreased salivary and lacrimal ﬂuid
secretion. Staining of lymphocytic inﬁltrates demonstrated
that the cell population was predominantly CD4+ with a
lesser portion (<10%) of CD8+ cells. No sex diﬀerences
were evident. By 20wks of age, no signiﬁcant diﬀerence
was observed between IgG1 levels in wild-type control
and transgenic mice and no autoantibodies were detected.
Interestingly, CD4+ Tc e l l si nIL-10 Tg mice expressed FasL,
suggesting that IL-10 may play a part in FasL activation
of nonspeciﬁc bystander T cells, which coincides with
Fas/FasL-mediated apoptosis in the destruction of acinar
tissue.
3.2.3. IL-12 Transgenic Mice. Interleukin-12 (IL-12) is
a heterodimeric cytokine produced mainly by activated
macrophages, dendritic cells, and granulocytes which func-
tions in the activation of NK cells and induces CD4+ Tc e l l
diﬀerentiation from a TH0t oT H1 cell phenotype [69, 70].
IL-12 SJL transgenic mice were made by expressing IL-12
p70 under the transcriptional control of the thyroglobulin
promoter, resulting in IL-12 overexpression in the thyroid
organ [69]. Histopathological analysis showed an increase in
mononuclear inﬁltrates within salivary and lacrimal glands
when compared with wild-type mice. LF consist primarily
of B220+ B lymphocytes with a lesser amount of CD4+ T
lymphocytes. Subsequently, the Tg mice develop hyposecre-
tory function in the exocrine glands. Sex-dependent growth
retardation was observed in female, but not male mice,
suggesting a sex-speciﬁc eﬀect of IL-12 overexpression [70].
A signiﬁcant decrease in saliva ﬂow rate was evident in both
sexes; however, in males the decrease was age dependent
while in females the change was neither age nor gene dose
dependent. Increased levels of ANA were observed at 13 wks,
andage-dependentincreaseinanti-SSB/Laautoantibodywas
also presented; however, no signiﬁcant diﬀerence in anti-
SSA/Ro autoantibody was seen when compared with wild-
type controls. Morphological changes included an increase
in acinar cell volume and a decrease in cell number per
acinus in the salivary glands [70]. This mouse model tends
to develop autoimmune thyroid disease, indicating the IL-
12 Tg mouse is a candidate animal model for secondary SjS
[69].
3.2.4. IL-14α Transgenic Mice. Interleukin-14α (IL-14α)i s
a cytokine produced mainly by T cells and acts as a
Bc e l lg r o w t hf a c t o r[ 71]. Increased levels of IL-14α are
present in the peripheral blood leukocytes of both pSjS
and secondary SjS patients with SLE [72]. IL-14α Tg mice
develop hypergammaglobulinemia involving IgG, IgA, and
IgM autoantibodies, parotid gland lymphocytic inﬁltrations,
deposits of IgM in the kidneys, and mild renal disease.
These features are characteristic of human SjS, but also
reﬂect a SLE-like phenotype [73]. Development of large B
cell lymphomas in aged IL-14α Tg mice occurs as a result
of dysregulation of IL-14α which regulates B lymphocyte
growth,acommonclinicalmanifestationinbothSjSandSLE
patients [73]. IL-14α Tg mice also demonstrate enhanced
antibody responses to vaccinations with T-independent and
T-dependent antigens. Decreased saliva secretion occurs
prior to lymphocytic inﬁltrations of the salivary glands.
Tear ﬂow has not been fully deﬁned, although lymphocytic
inﬁltrations do occur in the lacrimal glands. Less than 25%
of IL-14α Tg mice test positive for anti-SSA/Ro and anti-
SSB/La which are detected at 12 months of age in the salivary
glands, suggesting that other autoantibodies may contribute
to the initial phase of SjS development which remains to be
determined [72].
3.2.5. BAFF Transgenic Mice. B-cell activating factor (BAFF)
is a ligand in the tumor necrosis factor (TNF) family
w h i c ha c t sa sap o w e r f u lm o d u l a t o ro fBc e l la c t i v i t y[ 74].
BAFF is produced by myeloid cells and acts to induce
the polyclonal maturation of resting immature B cells to
resting mature B cells without stimulating proliferation
[75]. Several autoimmune diseases, including SLE and SjS,
have increased blood levels of BAFF, and neutralization of
BAFF results in disease prevention [76]. Mice transgenic
for BAFF develop an SLE phenotype, presenting with
hyperproliferation of B lymphocytes and elevated levels
of RF and anti-DNA autoantibodies [77]. As the BAFF
Tg mice age, they develop a secondary SjS-like phenotype
by 13 months of age with reduced saliva ﬂow, presenting
with enlarged salivary glands and corresponding B220+ cells
lymphocytic inﬁltrations with destruction of ductal and
acinar cells [78]. Keratoconjunctivitis was not apparent and
no sex dimorphism in disease development was observed.
BAFF Tg mice also had severe hypergammaglobulinemia
with high levels of immunoglobulins, speciﬁcally IgG, IgM,6 Journal of Biomedicine and Biotechnology
IgA, and IgE isotypes; however, neither anti-SSA/Ro or anti-
SSB/La autoantibodies were detected [79]. Summarized data
for spontaneous and transgenic mouse models is presented
in Table 3.
4. Knockout (KO) Mouse Models
4.1.Id3−/−Knockout Mice. Inhibitorofdiﬀerentiation3(Id3)
is a nuclear protein which inhibits the DNA binding of
basic-helix-loop-helix (bHLH) transcription factors and is
involved in both negative and positive regulations of cell
growth and diﬀerentiation [80]. Id3 is also inﬂuential in
TCR-mediated T cell selection during T cell development
[81]. Id3 null mutants develop lymphocytic inﬁltrations
within the salivary and lacrimal glands by 2 months of age,
corresponding with a loss in secretory function. Inﬁltrations
a r ec o m p o s e dm a i n l yo fC D 4 + and CD8+ T cells and
B220+ B cells [82]. Both autoantibodies, anti-SSA/Ro and
anti-SSB/La, were shown to be present at signiﬁcant levels
after 1 year of age [82]. Notably, inﬁltrations were not
observed in nonexocrine organs. In this model, neonatal 3
day thymectomization or genetic ablation of T cells resulted
in an improvement in disease condition, implying that
autoimmune T cells are of thymic origin. B cells were
observed to behave in cooperation with T cells in the
suppression of exocrine function.
4.2. PI3K Knockout Mice. The phosphoinositide 3-kinase
(PI3K) enzymes produce 3-phosphorylated phosphoinosi-
tides which function as second messengers downstream of
multiple receptor types [83]. To create a null mutant for
PI3K, a strain with a ﬂoxed allele of Pik3r1 and a null
allele of Pik3r2 was crossed with Lck-Cre transgenic mice,
producing the r1ΔT/r2n strain [84]. The resulting knockout
mouse develops an SjS-like autoimmunity, with lymphocytic
inﬁltration of the lacrimal glands and acinar cell atrophy
and destruction. Inﬁltrations in the lacrimal glands consist
primarily of CD4+ T cells with a lesser portions of CD8+
T cells and B220+ B cells. Inﬁltrations also occur within
the lungs, liver, and intestines, with no inﬂammation in the
kidney, supporting a primary SjS disease.
4.3. TGF-β1K n o c k o u tM i c e .The multifunctional cytokine,
transforming growth factor beta 1 (TGF-β1), is produced
mainly by lymphocytes, macrophages, and dendritic cells
and is involved in immunoregulation, embryonic develop-
ment, hematopoiesis, wound healing, ﬁbrosis, and tumor-
genesis [85–89]. Homozygous mutants of the TGF-β1 gene
experience a rapid onset of severe systemic inﬂammation
which predominantly targets the salivary glands, eyes, heart,
skeletal muscle, lungs, liver, stomach, pancreas, and brain
[90]. Inﬂammatory inﬁltrates vary in cellular compositions
across the spectrum of aﬀected organs, from primarily
lymphocytic in the brain to primarily neutrophilic in the
stomach. Salivary gland inﬁltrations appear at 1wk of age
andincreaseinseveritywithage[91].Mononuclearlympho-
cytic inﬁltration in the salivary gland causes rapid atrophy
of acinar tissues and high deposition levels of IgG, TNF-
α,I F N - γ,I L - 1 β, IL-4, IL-6, and IL-10 in the lesions. Saliva
production is signiﬁcantly aﬀectedin TGF-β1 KO mice when
compared to wild-type controls. Peripheral blood analysis of
TGF- β1KOmicerevealedthepresenceofanti-ssDNA,anti-
dsDNA, ANA, and glomerular immune complex deposits
[88]. TGF-β1 also aﬀects thymocytes diﬀerentiation by inhi-
bition of precursor CD4−CD8low thymocytes diﬀerentiation
into mature CD4+CD8+ thymocytes.
4.4. Thrombospondin-1-Deﬁcient Mice. Thrombospondin-1
(TSP-1) is a matricellular protein which regulates both in
vitro and in vivo activation of latent TGF-β [92, 93]. Relying
on the precise pathogenic eﬀect that TGF-β exerts on the
autoimmune process of SjS, a TSP-1 deﬁcient mouse strain
was created; however, the deﬁcient mice presented with less
severe inﬂammation when compared with the TGF-β KO
mouse [94]. Inﬂammatory inﬁltrates within the lacrimal
glands were ﬁrst observed at 24wks of age, consisting
primarily of CD4+ T cells with a lesser amount of CD8+
T cells. TSP-1-deﬁcient mice also demonstrate reduced eye
size which occasionally leads to complete closure and loss of
eyes. Damage to the corneal epithelial barrier is apparent,
occurring in conjunction with corneal edema in aged
mice. Both anti-SSA/Ro and anti-SSB/La autoantibodies are
detected at elevated levels in the sera, and a signiﬁcant loss
of lacrimal gland secretory function is evident. A twofold
increase in IL-17A+ cells was observed in splenocytes, and
increased apoptosis and transcriptional levels of IL-6 and
IFN-γ were seen in the lacrimal glands of 8-week- old mice.
Also, a considerable increase in IL-17A+CD4+ peripheral
T cells was apparent in 24 wks old TSP-1-deﬁcient mice,
concurrent with reduced levels of IFN-γ.C u r r e n t l y ,i ti s
unknown whether this mouse model develops sialadenitis
and secretory dysfunction in the salivary glands.
4.5. Aromatase-Deﬁcient Mice. The aromatase gene con-
t r o l sa c t i v a t i o no fe s t r o g e np r o d u c t i o n[ 95]. To determine
whether estrogen levels may contribute to SjS disease
pathogenesis, an aromatase knock-out (ArKO) mouse model
was constructed [96]. Male and female ArKO mice over 12
monthsoldpresentwithmildsplenomegaly,lymphadenopa-
thy, and hypercellularity in the bone marrow, with no
apparent lymphocytic inﬁltrations occurring within the
lungs and liver. Peripheral blood analysis revealed a 1.5- to
2-fold increase in leukocyte population with a signiﬁcant
increase in the number of B220+ Bl y m p h o c y t e s ,b u tn o
change in the number of T cell antigen receptor-β+ T cells.
Mild proteinuria and massive lymphocyte inﬁltration within
the kidneys suggest renal dysfunction in the ArKO mice. In
aged ArKO mice (12–17 months), enlarged salivary glands
with massive lymphocytic inﬁltrations were observed, with
severe acinar tissue destruction. The major composition
of lymphocytic inﬁltrations was B220+ Bl y m p h o c y t e s .A
signiﬁcant increase in B220+ cells was also observed in
the lymphoid tissues. Sera analysis revealed the presence of
anti-α-fodrin autoantibodies, and analysis of inﬁltrates in
salivary glands showed evidence of proteolytic fragments ofJournal of Biomedicine and Biotechnology 7
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α-fodrin, indicative of tissue destruction often present in
pSjS. The ArKO mice were negative for ANA and manifested
long-term estrogen deprivation resulting in autoimmune
exocrinopathy and occasionally renal failure.
5. ImmunizationMouse Models
5.1. Carbonic Anhydrase II Immunization. Frequently, anti-
bodies to carbonic anhydrase II (CAII), a basic zinc met-
alloenzyme involved in the catalysis of a reversible hydra-
tion of carbon dioxide, are characteristic of autoimmune
pancreatitis [97, 98]. However, recent ﬁndings suggest their
presence in other autoimmune diseases such as SjS as well
as connective tissue diseases [99]. Autoimmune sialadenitis
was induced in PL/J(H-2u) mice by immunization with
humancarbonicanhydraseII(CAII)[100].Miceimmunized
with CAII developed an increase in the size and focus score
in the salivary and lacrimal glands. In addition the ani-
mals manifested disintegration and atrophy of surrounding
acinar cells [100]. A small percentage of CAII-immunized
mice demonstrated smaller LF within the pancreas and
kidney, similar to human SjS patients who develop chronic
pancreatitis and renal tubular acidosis [100, 101]. Serum
antibody reactive to CAII has been reported in several
autoimmune diseases, including SjS, chronic pancreatitis
(CP), and autoimmune cholangitis [102]. However, no
proliferative responses of peripheral blood mononuclear
cells (PBMC) to CAII were observed, indicating CAII
is probably not a key target antigen for the immune
response in the origination and development of SjS and CP
[103].
5.2. Ro Immunization. Anti-SSA/Ro autoantibody is present
at a signiﬁcantly high level in patients with severe autoim-
mune diseases and serves as a standard diagnostic biomarker
for SjS and SLE [104]. BALB/c mice immunized with short
peptides from the 60-kDA Ro (SSA) antigen, known to
induce epitope spreading, develop an immune response to
the Ro/La ribonucleoprotein particle [105]. Ro immunized
mice present with lymphocytic inﬁltrations within the
salivary glands composed primarily of CD4+ (45%) and
CD8+ (18%) T cells and CD19+ ( 3 5 % )Bl y m p h o c y t e s ,c o n -
current with a signiﬁcant decrease in saliva ﬂow rate [105].
Intermolecular epitopes spreading can be prevented by oral
administration of the Ro 60 autoantigen to Ro immunized
mice, inhibiting salivary gland lymphocytic inﬁltrations and
increasing salivary ﬂow rate; however, epitope spreading is
indicative of minimal tolerance to Ro and La in the B cell
and T cell compartments [106–110]. This model however
requires repeated immunizations with Ro peptide emulsiﬁed
in Freund’s adjuvant over the course of several wks, with
disease development not occurring until 4 months, raising
the issue of a completely diﬀerent etiological scenario than is
seen in human SjS patients [111]. The role of anti-SSA/Ro is
not well understood in either SjS mouse models or in human
SjSpatients;therefore,furtherstudyisneededtoexaminethe
pathogenic role of Ro antigen.
6. Infection Mouse Models
6.1. Murine Cytomegalovirus. Environmental triggers have
been postulated to be capable of inducing autoimmu-
nity in genetically predisposed individuals. Several viruses
including Epstein-Barr virus (EBV), hepatitis C virus, and
cytomegalovirus(CMV)havebeenassociatedwiththedevel-
opment of SjS. Frequently, individuals who are immuno-
compromised develop sialadenitis upon CMV infection
due to viral replication which occurs primarily within the
ductal epithelium of the salivary glands [112]. In mice,
however, murine CMV (MCMV) instead replicates within
the serous acinar epithelial cells of the submandibular
gland [113–115]. Salivary gland infection in mice produces
an extended inﬂammatory immune response which leads
to epithelial cell death and regeneration [116]. Four dif-
ferent strains of mice (C57BL/6 [B6]-+/+, Fas-deﬁcient
B6-lpr/lpr, TNFRI-deﬁcient B6-tnfr1
0/0,a n dB 6 - tnfr1
0/0-
lpr/lpr) infected with murine CMV (MCMV) were shown
to manifest certain phenotypes of SjS-like disease [117].
For instance, Fas-deﬁcient B6-lpr/lpr mice infected with
murine CMV (MCMV) developed anti-Ro and anti-La
autoantibodies and persistent severe lymphocytic inﬁltra-
tions within the salivary glands that remained 100 days
postinfection even after viral clearance. Neither C57BL/6
[B6]-+/+norTNFRI-deﬁcientB6-tnfr
0/0 miceinfectedwith
MCMV had inﬂammation in the salivary glands at 100 days
postinfection, although inﬁltrations were observed in both
strains at 28 days postinfection. In MCMV-infected B6-
tnfr1
0/0-lpr/lpr mice, identical salivary gland inﬂammation
to MCMV-infected B6-lpr/lpr mice was observed at 28 days,
and no inﬂammation was apparent in uninfected B6-lpr/lpr
controls. All mice developed sialadenitis by 28 days which
was still present at 100 days postinfection.
Autoimmune-prone NZM2328 mice infected with
MCMV are also capable of recapitulating certain phenotypes
of SjS-like disease [118]. Infected female NZM2328 mice
have severe chronic lymphocytic inﬁltrations in the exocrine
glands composed of CD4+ T cells and B220+ B cells. Severe
local inﬂammations coincide with presence of organ-
targeted autoantibodies against glandular antigens as well
as reduced saliva volumes. Anti-Ro/SSA or anti-La/SSB
is not detected in virus-infected animals. However, both
infected male NZM2328 mice and female B6-lpr mice have
signiﬁcantly less severe glandular inﬁltrations. Interestingly,
animal models of MCMV-induced SjS only require a single
exposure to the virus which could serve as an ideal animal
modelexaminingtheearlyphaseofhumanSjSdevelopment.
7. TransplantationChimeras
Autoimmunity resembling a SjS phenotype can be induced
in hybrid mice upon transplantation of leukocytes from a
parental strain to nonirradiated F1 recipients, generating
a chronic graft-versus-host reaction (GVHR) [119–121].
Haematopoietic transplantation chimeras were produced
by transplantation of spleen cells from BALB/c donors to
nonirradiated F1-hybrids of BALB/c and CBA/H-T6 miceJournal of Biomedicine and Biotechnology 9
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[122]. Both male and female chimeras were shown to
subsequently develop a SjS-like phenotype with enlarged
lymph nodes and nodulated contorted spleens at 7 months
after transplantation. Males manifested a more severe disease
phenotype found in the lymph nodes and spleen when
compared to both female chimeras and wild type controls.
Sera were negative for autoantibodies against DNA, but
positive ANA with a nucleolar pattern was observed in most
chimeric mice. Raised levels of albumin in the urine of both
males and females were found, with higher levels in males.
Kidneys in both sexes demonstrated lymphocyte “cuﬀs” with
plasma cells surrounding the vessels and no IgG, IgA, or
IgM deposits were found in glomeruli. Mononuclear cell
inﬁltrates were apparent in both the salivary and lacrimal
glands of male and female chimeras with no diﬀerence in
severity between sexes. The spleens showed ordinary size and
distribution of red pulp, but diminished or absent white
pulp. The rim of lymphocytes was absent, and cells were
enlarged within the germinal centers. The nodules in the
spleen indicate that donor spleen colony-forming units have
invaded the recipient spleen, resulting in competition with
lymphohaematopoietic cells [122]. Therefore, it is likely that
transplantation leads to both acute and chronic GVHR. The
chimeric animals showed the absence of typical clinical phe-
notypes of SjS, including splenomegaly, hepatomegaly, high
albuminuria, anti-dsDNA autoantibodies, ascites formation,
and immune complex glomerulonephritis [122]. Summa-
rized data for knockout, immunization, infection, and trans-
plantation chimera mouse models is presented in Table 4.
8. Conclusion andFutureDirections
As demonstrated by the vast range of available mouse
models, SjS is a highly complex disease whose etiology is still
notwellunderstood. ItislikelythatSjSpathogenesisinvolves
an intricate relationship between genetics and environmen-
tal factors which can provoke both innate and adaptive
immunity, hormone secretion, and the autonomic nervous
system into triggering the initiation and progression of the
disease. Animal models demonstrate a variety of potential
pathologies for the disease, ranging from overproduction
of inﬂammatory cytokines to exposure by exocrine gland-
targeting viruses. Therefore, these animal models provide a
useful tool in observing the diﬀerent stages in the glandular
pathophysiological abnormality to the loss of immune toler-
anceandeventuallytotheonsetofovertorclinicaldisease.In
addition, they can serve as great tools in designing diagnoses,
as well as in prevention and treatment therapies. Each mouse
modelpossessesitsownadvantages,aswellaspitfalls,andno
idealmodel forthestudy ofSjScurrentlyexists. Spontaneous
models naturally develop SjS and appear most similar to the
human SjS disease, but still have their drawbacks. Knock-out
animal models can also be useful, allowing observation of
the importance a particular protein, regulatory mechanism,
or cell type has in disease development, leading to improved
treatment options. However, no SjS mouse model fulﬁlls all
of the necessary characteristics of the human disease, and
such discrepancies may cause progress in the ﬁeld to come
to a standstill. A better model is needed.
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